Creatinine ELISA Kit

Name: Creatinine ELISA Kit
SKU: DEIA-XYL4
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Urine, Forensic Matrices

Species Reactivity

Human; Research Animal

Detection Method

cELISA

Intended Use

For the determination of Creatinine levels in human urine.

Contents of Kit

1. EIA Buffer: 2×30 mL. Phosphate buffered saline solution with bovine serum and a preservative. Provided for dilution of samples. Ready to use.
2. Creatinine Standards: 110 μL of each standard. Standard 1 (S1) is a 10 mg/dL creatinine standard. Standard 2 (S2) is a 3 mg/dL creatinine standard. Standard 3 (S3) is a 1 mg/dL creatinine standard. Ready to use.
3. R1: Yellow Reagent: 20 mL. 0.6% Picric acid in sodium borate buffer. Must be combined with R2: Alkali solution in a five parts to one part ratio prior to use.
4. R2: Alkali Solution: 4 mL. 1N NaOH (Sodium Hydroxide). Must be combined with R1: Yellow Reagent in a one part to five parts ratio prior to use.
5. R3: Acid Reagent: 1.5 mL. Acetic acid mixture. Ready to use. Do not dilute.
6. Microplate: A 96 well Nunc microplate with 8 breakaway strips.

Storage

This kit can be used until the expiration date on the label when stored properly. Standards (S1, S2, and S3) and EIA Buffer must be stored at 2-8°C whereas all other kit components must be stored at room temperature. The kit is stable until the expiration date listed on the kit label.

General Description

The Creatinine ELISA Kit is a quantitative one-step kit designed for use as a quantitative analysis of creatinine levels in urine. The kit was designed for screening purposes and is intended for forensic use only.

Standard Curve

Citations

Have you cited DEIA-XYL4 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus

DIABETES THERAPY

Authors: Kim, Kyung-Soo; Hong, Sangmo; Ahn, Hong-Yup; Park, Cheol-Young

Abstract

Introduction The aim of this analysis was to evaluate the efficacy of lobeglitazone on albuminuria at 24 weeks of follow-up in patients with type 2 diabetes mellitus (T2DM) compared with pioglitazone using data from a randomized, double-blinded phase III trial. Methods In the phase III trial, patients who were inadequately controlled with metformin received 0.5 mg of lobeglitazone or 15 mg of pioglitazone for 24 weeks. Post hoc, exploratory analysis was used to investigate mean changes from baseline in the urine albumin-creatinine ratio (UACR) between the lobeglitazone (N = 104) and pioglitazone (N = 101) treatment groups. Results After 24 weeks of treatment, UACR was slightly decreased in the lobeglitazone group (- 4.3 mg/g creatinine [Cr]) compared to baseline and slightly increased in the pioglitazone group (5.2 mg/g Cr), with no change in the estimated glomerular filtration rate in either group; this difference was not statistically significant (P = 0.476). The incidence of new-onset microalbuminuria (2.4%) and the progression of albuminuria by > 1 stage (2.9%) in the lobeglitazone group were lower than the respective values in the pioglitazone group (6.8 and 6.1%, respectively). Of the patients in the lobeglitazone group, 50% exhibited regression to normoalbuminuria, compared to 39.3% of the patients in the pioglitazone. In subjects in the lobeglitazone group with micro- and macroalbuminuria, UACR tended to be more decreased and HbA1c was more reduced compared to those with normoalbuminuria (P = 0.014). Conclusion Lobeglitazone had a tendency to improve albuminuria in patients with T2DM and had comparable effects on albuminuria as pioglitazone which has demonstrated beneficial effects.

The effect of ejection fraction on mortality in Coronary Artery Bypass Grafting (CABG) patients

PAKISTAN JOURNAL OF MEDICAL SCIENCES

Authors: Awan, Nabil Iftikhar; Jan, Azam; Rehman, Mujeeb Ur; Ayaz, Narmeen

Abstract

Background and Objectives: Patients with low ejection fraction undergoing isolated CABG surgery are at a higher risk for postoperative complications and mortality. This study was conducted to evaluate the impact of ejection fraction on the outcome of isolated Coronary Artery Bypass Grafting (CABG). Methods: Between July, 2017 to May, 2019 total 1214 patients underwent isolated CABG. Patients were divided into three groups based on their pre-operative Ejection Fraction (EF). Group-I included 625 patients with EF >50% [Normal EF], Group-II included 484 patients with EF 35-50% [Mild to Moderately Reduced EF], and Group 3 included 105 patients with EF<35% [Severely Reduced EF]. Results: The mean age of Group-I was 57.58 +/- 9.206, Group-II was 58.38 +/- 9.124 and Group-III was 58.81 +/- 8.663.The male gender was the predominant gender in all three groups: 194(41.1%) in Group-I, 201(52.6%) in Gp2, 52 (61.9%) in Group-III. 231(36.9) patients in Group-I, 234(48.3)in Group-II and 59(56.2) in GroupIII had raised creatinine pre operatively. 5(0.8%) patients in Group-I, 2(0.4%) in Group-II and 3(2.9%) in Group-III had history of CVA. Hypertension was present in approximately 60% of all our patients. In the peroperative period 20(3.2%) patients in Group-I required an IABP as compared to 73(15.1%) in Group-II and 41(39.0%) in Group-III. The mean post-operative mortality in Group-I was 19 (3%), Group-II was 24(5.0%) and low EF group was 9(8.6%). Conclusions: The results clearly indicate that worsening pre-operative ejection fraction is associated with a higher mortality post-operatively in patients undergoing isolated CABG. In addition, use of IABP increases as pre-operative LVEF decreases.